BRISBANE, Calif. — November 26, 2025 — Leads & Copy — Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on immunological diseases, has appointed James R. Meyers to its Board of Directors.
Meyers brings over 30 years of commercial leadership experience in the biopharmaceutical industry. Vera Therapeutics’ Founder and CEO, Marshall Fordyce, said Meyers’ expertise in commercial, public policy and access will be integral to the company’s growth as it prepares to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other autoimmune diseases.
Meyers said he is privileged to join Vera Therapeutics’ board and be part of the company’s growth. He added that he is attracted to Vera Therapeutics’ focus on changing the course of immunological diseases for patients who would otherwise be facing devastating outcomes.
Meyers worked at Gilead from 1996 until December 2021, most recently as a Senior Advisor. He was Executive Vice President of Worldwide Commercial Operations, responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. He led product launches in HIV and HCV therapeutic areas.
During his time at Gilead, Meyers was part of a group of executives who led the transition of the company from an innovative start-up to a global biopharmaceutical company that delivered more than $28 billion in revenue in 2024. Prior to Gilead, Meyers held positions with AstraZeneca. From 2020 to 2024, Meyers served as President and CEO of IntraBio Ltd. He currently serves on the Board of Directors of Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc. He is also a Senior Advisor at BCG. Meyers holds a B.S. in Economics from Boston College.
Vera Therapeutics is focused on developing treatments for serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful.
Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868.
Joyce Allaire, LifeSci Advisors, 212-915-2569, jallaire@lifesciadvisors.com
Debra Charlesworth, Vera Therapeutics, 415-854-8051, corporatecommunications@veratx.com
Source: Vera Therapeutics
